Positron Corporation Enters Industry Partnership Agreement with MedAxiom

Rhea-AI Summary

Positron Corporation (OTC: POSC), a molecular imaging technology company specializing in PET and PET-CT systems, has announced a strategic partnership with MedAxiom, a leading cardiovascular performance solutions provider.

The partnership connects Positron with MedAxiom's extensive network of cardiovascular organizations, physicians, and thought leaders. This collaboration will provide Positron with market intelligence, clinical insights, and collaboration opportunities to support broader adoption of PET-CT technology in cardiovascular care.

MedAxiom's Executive VP Joe Sasson highlighted the rapid growth of Cardiac PET in transforming cardiovascular care, while Positron's President Adel Abdullah emphasized the partnership's potential to expand their user base and accelerate adoption of their imaging solutions.

Positive

• Access to MedAxiom's extensive network of cardiovascular organizations and physicians
• Partnership provides valuable market intelligence and clinical insights
• Potential for accelerated adoption of PET-CT technology
• Strategic positioning in the growing cardiac PET market

Negative

• None.

News Market Reaction

+3.57%

1 alert

+3.57% News Effect

On the day this news was published, POSC gained 3.57%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Buffalo, NY, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging technology company specializing in PET and PET-CT imaging systems and clinical services is pleased to announce a partnership with MedAxiom, the cardiovascular community’s premier source for organizational performance solutions. 

MedAxiom is recognized nationwide for its extensive network of physicians, clinicians, and administrators, and for driving innovation and best practices that improve outcomes and performance across cardiovascular medicine.

As a MedAxiom industry partner, Positron is connected to the nation’s leading cardiovascular organizations, gaining valuable insights and exposure that advance the adoption of the PET modality. This collaboration provides unparalleled access to hundreds of organizations and thousands of physicians, clinicians, and thought leaders who are driving advancements in nuclear cardiology. Engagement with the MedAxiom community will provide Positron with market intelligence, clinical insight, and opportunities for collaboration that support broader adoption of PET-CT technology and improved patient care.

"Cardiac PET is transforming cardiovascular care, and its rapid growth shows no signs of slowing,” said Joe Sasson, PhD, MedAxiom’s executive vice president of Ventures and chief commercial officer. “As programs increasingly adopt this advanced diagnostic tool in pursuit of high-quality care, MedAxiom looks forward to partnering with Positron to bring valuable education, innovative solutions, and meaningful operational insights to our community of cardiovascular leaders."

Adel Abdullah, President of Positron, commented, “MedAxiom is a trusted leader in cardiovascular excellence, and we are proud to join such a valuable network. This partnership connects Positron with a community at the forefront of transforming cardiovascular care through the PET modality. It is an exciting time for both Positron and the nuclear cardiology field, and MedAxiom will be a tremendous resource helping us expand our user base and accelerate adoption of our imaging solutions.”

About Positron Corporation

Positron Corporation is a medical technology company that co-develops, manufactures, and sells state-of-the-art PET and PET-CT imaging systems and clinical services to nuclear medicine healthcare providers throughout North America.

Positron specializes in the field of cardiac Positron Emission Tomography (PET) imaging, the gold standard in cardiac diagnostics. Positron’s innovative PET/PET-CT technologies, clinical services and practice solutions enables healthcare providers to accurately diagnose coronary artery disease and improve patient outcomes while practicing cost effective medicine.

Positron's PET and PET-CT imaging systems and distinct market position are substantial advantages unique to Positron that will facilitate the adoption of cardiac PET and the growth of the nuclear imaging market. Positron will soon offer a state-of-the-art PET-CT 4D molecular imaging device in the Affinity PET-CT 4D 64-Slice. Positron’s PET-CT(s) will enable nuclear cardiologists to utilize the full capabilities of molecular imaging and nuclear medicine. Positron’s PET-CT systems will also enable the Company to fully service and meet the demands of the vast oncology imaging segment of nuclear medicine. 

Positron is committed to expanding the cardiac and oncology PET modality by delivering the best technology and value to imaging specialists and will continue to advance its technology through its co-developer, supplier, and R&D venture with Shenyang Intelligent Neuclear Technology Co. a subsidiary of Neusoft Medical Systems.  

Please visit the Company’s website at: www.positron.com.

Forward-Looking Statements                             
This press release contains statements which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Positron Corporation, and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results even if new information becomes available in the future.

FOR FURTHER INFORMATION, please visit the company’s website at www.positron.com, or contact: investor@positron.com

Investor Relations Contact:
Skyline Corporate Communications Group, LLC
1177 Avenue of the Americas, 5th Floor
New York, New York 10036
info@skylineccg.com

FAQ

What is the significance of Positron's (OTC: POSC) partnership with MedAxiom?

The partnership connects Positron with MedAxiom's nationwide network of cardiovascular organizations and physicians, providing market intelligence and collaboration opportunities to advance PET-CT technology adoption.

How will the MedAxiom partnership benefit Positron Corporation (POSC)?

The partnership provides Positron with access to hundreds of organizations and thousands of physicians, market intelligence, clinical insights, and opportunities to expand their user base and accelerate adoption of their imaging solutions.

What is the current state of Cardiac PET technology according to MedAxiom?

According to MedAxiom's EVP Joe Sasson, Cardiac PET is transforming cardiovascular care with rapid growth that shows no signs of slowing, as programs increasingly adopt this advanced diagnostic tool.

Who are the key executives involved in the Positron-MedAxiom partnership?

The key executives mentioned are Joe Sasson, PhD, MedAxiom's Executive VP of Ventures and Chief Commercial Officer, and Adel Abdullah, President of Positron Corporation.

What type of imaging technology does Positron Corporation (POSC) specialize in?

Positron Corporation specializes in PET and PET-CT imaging systems and clinical services for molecular imaging technology.